Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study by Smithy, James W, Kalvin, Hannah L, Ehrich, Fiona D, Shah, Ronak, Adamow, Matthew, Raber, Vladislav, Maher, Colleen A, Kleman, Jenna, McIntyre, Debra A G, Shoushtari, Alexander N, Betof Warner, Allison, Callahan, Margaret K, Momtaz, Parisa, Eton, Omar, Nair, Suresh, Wolchok, Jedd D, Chapman, Paul B, Berger, Michael F, Panageas, Katherine S, Postow, Michael A

Get full text